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Abstract
Introduction: Down syndrome (DS), a genetic variant of early onset Alzheimer’s disease (AD), lacks a suitable outcome measure for prevention trials targeting predementia stages.
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Methods: We used cognitive test data collected in several longitudinal aging studies
internationally from 312 participants with DS without dementia to identify composites that were sensitive to change over time. We then conducted additional analyses to
provide support for the utility of the composites. The composites were presented to an
expert panel to determine the most optimal cognitive battery based on predetermined
criteria.
Results: There were common cognitive domains across site composites, which were
sensitive to early decline. The final composite consisted of memory, language/executive
functioning, selective attention, orientation, and praxis tests.
Discussion: We have identified a composite that is sensitive to early decline and thus
may have utility as an outcome measure in trials to prevent or delay symptoms of AD
in DS.
KEYWORDS

Alzheimer’s disease, clinical trial outcome, composite measure, Down syndrome, early cognitive
decline

1

BACKGROUND

declines in memory (recall of new information) and attention occur first
in DS,9,13 similar to sporadic AD. Other DS studies have found that

Down syndrome (DS), most commonly caused by a triplication of chro-

impairments in executive functioning and behavioral and psychological

mosome 21, is considered a genetic variant of early onset Alzheimer’s

changes precede difficulties in memory.14 Determining which abilities

disease (AD). As a consequence of trisomy 21, individuals with DS

first show AD-related decline during the transition to the prodromal

have three copies of the amyloid precursor protein (APP) gene.

phase and identifying the tests most sensitive to change in this period

This significantly increases the risk of amyloid beta (Aβ) deposition

is vital to determine the most optimal point for an intervention.15 If

as plaques and consequently the development of

dementia,1

with

a given test is found to be the most sensitive (ie, earliest to change),

over 95% of individuals eventually developing clinical features of

then by implication it will likely be a cognitive modality quickest to

AD.2

change.

The ultra-high risk for AD in association with a high diagnostic cer-

To facilitate the development of the first AD prevention trials in

tainty for an underlying Alzheimer pathology in cases with dementia

DS, there is a need to refine and adapt current tests of cognition and

makes people with DS an important population to consider for ran-

identify those which are most sensitive to early AD-related impair-

domized controlled trials (RCTs) for interventions that seek to prevent,

ments and, therefore, predictive of dementia before the diagnosis can

delay, or halt the development and progression of dementia.3

Although

be made. Such a test battery would also be valuable to clinicians by pro-

there is growing interest in including people with DS in intervention tri-

viding them with predictive measures for tracking AD-related decline.

als, barriers remain for RCTs, including the need for reliable cognitive

To this end, we utilized data from existing longitudinal studies associ-

outcome measures of progression during the preclinical to prodromal

ated with the Horizon 21 DS consortium (H21 consortium),4 as well as

spectrum stages of dementia.4

from two DS research cohorts in the United States. The advantages of

Identifying early subtle changes in cognition and diagnosing AD

this approach include providing a more diverse sample of cognitive data

in DS can be challenging because of the presence of developmen-

from individuals with DS than is typically possible in single-site studies.

tal cognitive impairments associated with lifelong intellectual disabil-

It also capitalizes on the expertise of multiple research groups and pro-

ity (ID) and the variability in baseline cognitive functioning across

vides an opportunity to cross-validate the findings of one cohort with

individuals.5 However, there are several cognitive tests measuring

another in the presence of population, cultural, and language differ-

memory, verbal fluency, planning, inhibition, attention and visuo-motor

ences.

abilities which appear to be appropriate for discriminating between

Our aim was to use a data-driven approach to identify cognitive

those with and without dementia and tracking AD-related decline and

tests or test items that are the most sensitive to detecting early cog-

progression.6–12 Although these tests show promising results in dis-

nitive change in adults with DS. We then sought to use these results

tinguishing individuals with and without dementia and may be use-

as well as expertise from clinicians and researchers familiar with the

ful as cognitive endpoints for RCTs, it is currently unclear which tests

cognitive tools to identify the optimal constellation of tests or test

show the earliest decline (before dementia can be diagnosed clini-

paradigms to constitute a composite cognitive assessment battery to

cally) for use in prevention trials. There is evidence to suggest that

use in future RCTs in DS and in clinical settings.
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2

METHODS
RESEARCH IN CONTEXT

2.1

Cohorts

1. Systematic review: A literature search was conducted
using the Scopus database. People with Down syndrome

Longitudinal data were used from five observational studies on age-

(DS) are at an ultra-high risk of developing Alzheimer’s

associated cognitive change in DS. These sites included data from

disease (AD) as they age. Although there are currently

the Horizon21 study group including the London Down Syndrome

tests that are effective at identifying those with and with-

(LonDownS) Consortium in London, UK,12,13 the Dementia in Down

out AD, there is limited research on tests, which are sensi-

syndrome (DiDs) research cohort in Cambridge, UK,16,17 and the

tive to prodromal changes for use in preventative clinical

Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) clinical

trials of AD in DS.

cohort in Barcelona, Spain,6,18 in addition to several DS longitudinal

2. Interpretation: We provide an important component in

research cohorts from the United States (Neurodegeneration in Aging

expediting the inclusion of people with DS in preven-

Down Syndrome [NiAD] from the Universities of Pittsburgh and

tative clinical trials with the development of the H21

Wisconsin, Madison19 ), and the Aging in Down syndrome (ADS) study

AD test battery. It consists of measures of memory, lan-

from University of Kentucky20 ). Informed consent was obtained from

guage/executive functioning, selective attention, orienta-

participants in all cohorts. Because the goal of this project was to

tion, and praxis and is a short and comprehensive out-

define a cognitive composite endpoint that is sensitive to change in

come measure.

clinically healthy participants, we restricted our analyses to individuals

3. Future directions: Further examination of the H21 AD

who were 35 years of age or older (as this is the age group within which

battery is now required to examine its association with

demonstrable AD pathology is present in DS) and who did not have

known AD biomarkers.

a clinical diagnosis of dementia at their baseline visit. Furthermore,
as we were interested in rates of cognitive decline, we included only
participants who had at least two assessments (at baseline and one
or more follow-ups) so that a rate of change could be estimated; all
participants with a minimum of two assessment timepoints (at least 6

verted this outcome to a Cohen’s d statistic for ease of comparison

months apart, with mean length of follow-up between study cohorts

across cohorts.

varying from 1.97 to 3.9 years) were included regardless of other

We repeated steps 2-4 iteratively to evaluate a variety of cogni-

comorbidities to ensure a representative sample (those with severe ID,

tive composite scores. We first analyzed each cognitive test in isola-

significant sensory impairments, or other acute illness that precluded

tion; then we averaged two tests together, then three and so on up to

cognitive testing were excluded from assessments at the site level).

a maximum of six tests in a single composite. This process occurred for

For participants with multiple assessment timepoints, a slope was

all tests available for a given cohort, resulting in dozens of composite

estimated across all timepoints. In total, 312 participants met inclusion

scores that consisted of the average of between one and six cognitive

criteria; the number of participants by site, number of visits, and other

tests. For each composite, the Cohen’s d scores were extracted from

demographic variables are listed in Table 1. Each site administered

the LME model and then rank ordered in terms of absolute magnitude.

a unique test battery spanning several different cognitive domains,

Composites with the highest scores were retained for further analy-

and the specific tests used in each battery are listed in Table S1 in the

sis/discussion. Any test that appeared in three of the five top composite

supplementary material.

scores was assumed to tap a cognitive domain (eg, attention, memory,
executive function) that shows large and consistent decline in individuals who likely have preclinical AD. We then used these tests to form an

2.2

Statistical analysis

“optimal” composite consisting of the z-scored average of each of the
measures.

Due to differences in the cognitive tests that were administered as
well as the length and frequency of follow-up, all analyses were conducted separately within each available cohort. We were interested in

2.3

Evaluation of the optimal composite

the rates of change on each cognitive test and therefore conceptualized “years since baseline visit” as the time variable (hereafter referred

After selecting the composite within each cohort with the greatest sen-

to as “time”). Our modeling strategy then proceeded in several steps.

sitivity to decline, we conducted additional analyses to provide sup-

First, all neuropsychological scores were z-scored to the baseline visit.

port for the utility of such a composite in a global clinical trial. First,

Second, a linear mixed-effects model was constructed using the “lme4”

we examined individual rates of change on the composite score within

package21 to predict scores on a given cognitive test from the “time”

each cohort as a function of critical demographic variables. Specifically,

variable. Random intercepts across participants were included in all

annualized rates of change for each participant were extracted from a

models. Third, we extracted the beta weight of “time” from the model

linear mixed-effects model predicting change in the composite score

that indexes the annualized rate of change in z-scores. Fourth, we con-

over time. These rates of change were then further regressed onto
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TA B L E 1

Demographic data from each cohort

Barcelona

London

Pittsburgh/Wisconsin

Cambridge

Kentucky

N

128

103

31

19

31

Age (y)

43.8 (6.5)

47.4 (6.6)

42.8 (4.6)

44.1 (5.2)

44.6 (7.0)

Sex

M = 63 (49%)
F = 65 (51%)

M = 59 (57%)
F = 44 (43%)

M = 19 (61%)
F = 12 (39%)

M = 11 (58%)
F = 8 (42%)

M = 9 (29%)
F = 21 (68%)

Level of Intellectual
Disability

Mild = 34 (27%)
Mod = 72 (56%)
Severe = 22 (17%)

Mild = 40 (39%)
Mod = 41 (40%)
Severe = 22 (22%)

Mild = 14 (45%)
Mod = 7 (23%)
Severe = 2 (6%)

Mild = 7 (37%)
Mod = 11 (58%)
Severe = 0 (0%)

Mild = 18 (58%)
Mod = 13 (42%)
Severe = 0 (0%)

Hearing Problems

No = 112 (88%)
Yes = 14 (11%)

No = 23 (22%)
Yes = 78 (76%)

NA

No = 12 (63%)
Yes = 6 (32%)

No = 4 (13%)
Yes = 25 (81%)

Vision Problems

No = 31 (24%)
Yes = 34 (27%)

No = 80 (78%)
Yes = 22 (21%)

No = 16 (52%)
Yes = 15 (48%)

No = 3 (16%)
Yes = 5 (26%)

No = 8 (26%)
Yes = 21 (68%)

Psychotropic Medication

No = 51 (40%)
Yes = 38 (30%)

No = 73 (71%)
Yes = 22 (21%)

No = 23 (74%)
Yes = 8 (26%)

No = 17 (89%)
Yes = 2 (11%)

NA

APOE

NA

No e4 = 75 (73%)
Has e4 = 22 (21%)

No e4 = 28 (90%)
Has e4 = 3 (10%)

No e4 = 13 (68%)
Has e4 = 4 (21%)

No e4 = 11 (35%)
Has e4 = 3 (10%)

Number of Visits

3.1 (1.0)

2 (0)

2.3 (0.5)

3.4 (0.8)

3.6 (0.8)

Mean length of
Follow-up (y)

2.5 (1.1)

1.97 (0.06)

3.9 (1.1)

3.7 (1.3)

2.6 (0.7)

Note: Variables are listed as mean (standard deviation) for continuous variables and N (percentage) for categorical variables. Percentages may not sum to
100% due to the presence of missing demographic information.

age, sex, pre-study level of ID at baseline, and length of follow-up to

3

RESULTS

determine which, if any, entry criteria influence rates of change. Second, exploratory power analyses were conducted using the longpower

The average Cohen’s d of the top five cognitive composites in each

package22 in R. Specifically, we estimated the number of participants

cohort ranged from small: 0.28 for Barcelona, to moderate: 0.44

needed to detect either a 50% slowing or a 30% slowing in the rate of

for Kentucky, to large: 1.13 for London, 1.20 for Cambridge, and

change for either a 2-year or 3-year clinical trial, as this range repre-

1.8 for Pittsburgh/Wisconsin. Cognitive tests, which appeared in at

sents a realistic and clinically significant effect size for AD prevention

least three of the top five composites are shown in Table 2, colored

trials.

by cognitive domain. Measures of memory, language, attention, and
praxis-type tests were consistently represented across all cohorts.
The means of the “optimal” composite at the baseline and follow-

2.4

Consensus discussion

up visits are plotted in Figure 1. Annualized rates of change (Figure 2) extracted from linear mixed effects showed cognitive decline

Finally, considering the above information, an expert panel of clinicians

on this composite in all five samples (Pittsburgh/Wisconsin: β = −0.10,

and researchers from each site represented in the consortium includ-

SE = 0.02, P < .001; Kentucky: β = −0.09, SE = 0.05, P = .055; London:

ing co-authors (RAB, BB, JBW, BLH, JJ, SVL, SS, FAS, JH, AS) met to

β = −0.11, SE = 0.02, P < .001; Barcelona: β = −0.03, SE = 0.01,

discuss the feasibility of utilizing specific tests in a global clinical trial.

P = .03; Cambridge: β = −0.07, SE = 0.03, P = .02). Regression anal-

The clinicians and researchers who took part in the consensus meeting

yses of the individual rates of change on this composite indicated

were all well established and experienced in working with adults with

that age at baseline (β = −0.001, SE = 0.0003, P < .001) and pre-

DS, DS and AD, and clinical trials involving patients with AD. After a

study level of ID (β = 0.01, SE = 0.003, P = .003) significantly pre-

series of group discussions, an optimal cognitive battery was defined

dicted rates of change. Sex and length of follow-up were not significant

based on the following criteria: (1) it must measure domains that the

predictors.

statistical analyses indicated show the largest decline over time; (2)
the tests must be amenable to administration in a global trial (ie, not
culturally specific, limit language effects if applied across different lan-

3.1

Power analysis

guages); (3) it must be feasible in terms of administration; (4) it must
have face validity as outcome measures of decline related to AD in

As the London cohort had a consistent length of follow-up of ≈2 years

RCTs; and (5) it must have low floor and no major ceiling effects in

and a good sample size, this cohort was used as the natural history

healthy adults with DS.

group to evaluate power. Power analyses were conducted to estimate
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TA B L E 2

List of tests that appeared in the top five composites for each cohort

Barcelona

London

Pittsburgh/Wisconsin

CAMCOG-DS Orientation
(−0.03)
Digits span backward (−.09)

CAMCOG-DS
Orientation (−0.78)
CANTAB Pal (−0.58)

Forward Corsi (−0.43)
CRT Cued Delayed Recall
(−0.87)

CAMCOG-DS Praxis (−0.13)

Finger-nose pointing
(−0.62)

Purdue Pegboard Test (−1.13)

CAMCOG-DS Praxis
(−0.71)

Expressive one-word (−1.1)
NEPSY Fluency (−0.90)

CAMCOG-DS Fluency
(−0.42)
CAMCOG-DS Language
(−0.71)

CAMCOG-DS
Comprehension (−.11)

Cancellation task (−.09)

Cambridge

Kentucky
SIB Orienting to Name
(−0.24)
SIB Praxis (−0.16)

CANTAB SRT (−0.82)

CAMCOG-DS Attention
(−0.31)

CEFA Tower of London
(−0.84)

CEFA Cats and Dogs (0.17)

SIB Social Interactions
_(−0.15)
SIB Visuospatial ability
(−0.38)

Cohen’s D of the rate of change for each test is listed in parentheses.
CAMCOG, Cambridge Cognition Examination; CANTAB SRT, Cambridge Executive Functioning Assessment Simple Reaction Time; CANTAB PAL, Cambridge
Executive Functioning Assessment Paired Associate Learning; CEFA, Cambridge Executive Functioning Assessment; NEPSY, A Developmental NEuroPSYchological Assessment; CRT, Cued Recall Test; SIB, Severe Impairment Battery.
Cognitive domains.
Memory & Orientation.
Attention/Praxis.
Executive Functions.
Language.
Praxis.
Visuospatial abilities

Optimal Composite Means at
Baseline and Follow−up

Annualized change for each cohort
0.00

cohort

0.0

Barcelona
Cambridge
Kentucky

−0.2

London
Pittsburgh/
Wisconsin

−0.4

Annual Change

Composite

0.2
−0.05

−0.10

−0.15

Barcelona

1

Cambridge

Kentucky

2

Pittsburgh/
Wisconsin

Cohort

Time
F I G U R E 1 Optimal composite means from each cohort at the
baseline and follow-up visit

London

F I G U R E 2 Annualized rates of change extracted from the linear
mixed effects

3.2

Consensus discussion

the required sample size to detect a given effect size assuming 80%

Taking into account the above data, and the predefined parameters for

power, with trial durations of either 2 or 3 years. Results of the power

selecting tests of interest, the following decisions were made from the

analyses are summarized in Table 3. An expected 210 participants (con-

tests listed in Table 2: two tests were chosen as the consensus tests for

fidence interval [CI] = 110-545) would be needed in each group (treat-

memory abilities; a modified version of the Cued Recall test (mCRT)6,23

ment and placebo) to detect a 30% slowing of decline. This number

and the CANTAB paired associate learning test (PAL)24 ; this was due to

could be reduced to 150 per group (CI = 79-389) if assessments were

the importance of memory (by accepted diagnostic criteria) in the early

collected every 6 months rather than annually due to improvement in

stages of AD-related decline and the variety of different tests that were

stability of measurements.

present in the composites from each cohort. With regard to language
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TA B L E 3 Estimated sample sizes (means and confidence intervals) needed to detect a given effect size for a given trial duration and
assessment frequency in the London cohort
50% Effect Size
Frequency

30% Effect Size

2y

3y

2y

3y

6 mo

151 (79-392)

54 (28-141)

419 (220-1090)

150 (79-389)

Annual

189 (99-490)

75 (40-196)

524 (275-1362)

210 (110-545)

Note: estimates are per treatment arm.

abilities, verbal fluency (a simple animal fluency task with 60-second

issues associated with single research group studies such as admin-

time limit) was the consensus test. There was a consensus that exist-

istration and language or cultural effects. Earlier studies highlighted

ing executive functioning tests may not be reliable in this population

the importance of decline in memory,23,28 attention,13,25 and executive

and frequently demonstrate floor effects, as they are too difficult in

functioning,29 with declines involving memory and attention occurring

DS populations. Because ideational fluency is often regarded as a mea-

before that of declines in measures of executive function in machine-

sure of executive functioning, it was felt that verbal fluency could serve

learning models.9

as a measure of this domain as well. The Cancellation

task,25

a test of

Because AD in DS has, just like in other populations, a strong rela-

selective attention, was selected as the measure of attentional abilities.

tionship with age, it is to be expected that older adults (and cohorts

Although the CANTAB simple reaction time test (SRT) would have been

with higher mean age) would show larger changes on cognitive mea-

ideal given the inclusion of the CANTAB PAL, the SRT task has been

sures over time, which was confirmed in our analyses. We also showed

discontinued and is no longer available for use in research studies. The

that the degree of premorbid ID influenced effect sizes, which may

Purdue Pegboard test26 was chosen as the test of praxis-type abilities

be due to those with more severe ID having lower baselines scores,

and finally; the orientation subtest of the CAMCOG-DS27 was the con-

thus limiting the amount of decline that can be measured over time,

sensus test for orientation (see Table 4 for full details).

and/or due to greater variability of scores for a given individual, as
it is harder to administer the test reliably for those who are more
intellectually impaired. Although we did not demonstrate any signif-

4

DISCUSSION

icant relationships between length of follow-up and effect sizes of
decline on measures when age, ID level, and sex are taken into account,

This is the first comprehensive analysis of cognitive decline associated

this may become apparent in studies with longer follow-up and could

with AD in DS across cohorts regardless of assessment tools used, with

potentially explain differences between previously reported studies, as

a focus on decline during the earliest transition from the preclinical to

the effect size could be small. Other reasons for differences in effect

the prodromal stage of AD before a clinical diagnosis of dementia. We

sizes between cohorts are the different tests used within the selected

demonstrated a range of effect sizes for different cognitive composites

domains; specific tests used within one cohort but not another may

and between cohorts; the latter was partially explained by baseline dif-

assess subdomains, which are more sensitive to early decline, creating

ferences in age and intellectual impairment. Not surprisingly, partici-

a discrepancy in the magnitude of the effect reported. Other poten-

pants who are older at entry were more likely to decline over the course

tial reasons may be that people who start to show decline have been

of the study. We then identified cognitive domains and specific neu-

dropped out from longitudinal assessments and the threshold at which

ropsychological tests that were consistently represented as important

people are not offered testing could have differed between sites; or

(ie, sensitive to change) across all cohorts. Our final composite score

potential differences in thresholds for clinical dementia diagnosis that

included measures of memory, language/executive functioning, selec-

have determined selection of participants included in this analysis.

tive attention, orientation, and praxis. Annualized rates of change on

We excluded participants with an AD diagnosis at baseline, but cross-

this composite showed cognitive decline in all the cohorts, thus demon-

country differences between cohorts in their criteria of diagnosing AD

strating its validity in tracking change during the early stages of AD.

could have an impact on whether the remaining participants are likely

Expert opinion was employed to select tests to use in a final compos-

to show change over time, if, for example, those in early prodromal

ite for use as outcome measure in clinical trials based on feasibility and

stage have been already given an AD diagnosis.

known properties in individuals with DS.

4.1
Patterns of decline associated with
development in AD in DS

4.2
Outcome measure in clinical trials of
treatment to delay cognitive decline in DS individuals
There is renewed interest in the need to target the earlier stages of AD

This study confirms a pattern of decline that has been emerging in

in the context of a series of failed therapeutics in later stage disease

studies of cognitive AD-related change in DS. For the first time, data

(including of symptomatic therapies in DS30,31 ;). DS represents a rel-

from several data sets have been combined, thus avoiding some of the

atively large population in which such trials are more feasible (due to
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TA B L E 4

Details of the recommended test battery

Domain(s)

Test and administration
time

Administration & scoring

Primary outcome of
interest

Cued Recall test,
modified version
(mCRT)6,23
20 min

The mCRT consists of a learning phase and a testing
phase; during the learning phase, 12 items
representing distinct semantic categories are
presented on 3 four-item cards, with each item
accompanied by a unique category cue (Buschke,
1984). Learning is repeated up to a maximum of
three times if necessary. The testing phase consists
of three trials of free and cued immediate recall,
generating two measures, a free immediate recall
score (FIRS; spontaneous recall of the list of 12 items
for each trial) and a total immediate score (TIS; FIRS
plus items recalled when the category cue was
provided). A 20-min delayed recall trial has also been
included, generating two additional scores: free
delayed recall score (FDRS) and a total delayed score
(FDRS plus items recalled after category cue was
provided). Scoring as per Devenny et al., 2002, and
Benejam et al., 2015.

Cued delayed recall

CANTAB paired associate
learning test (PAL)24
10 min

Computerized measure of visuospatial short-term
memory from the CANTAB battery (CANTAB, 2016);
extended clinical version, with rater rather than
automated prompts; Startin et al., 2015). First trial
score was used. Participants are required to
remember locations of an increasing number of
patterns in progressive stages, hidden behind
“boxes” on the screen. The main outcome from this
test is the first trial memory score: the number of
pattern locations correctly remembered on the first
trial for each stage attempted. The secondary
outcome is the number of stages completed.

PAL first trial memory
score

Language/ executive
functioning tests

Verbal Fluency34
1 – 2 min

Animal fluency test; number of animals named in 60 s.
Total correct score and adjusted score (0 – 4) are
used.

Total raw score. Adjusted
scores based on the
CAMCOG-DS scoring
can also be used.

Selective attention

Cancellation task25

Participants are shown a piece of paper with a clutter of
black and white items, and asked to cross-out each
occurrence of a target item, following a practice trial.
Total time to complete the task and total number of
correct targets crossed-out are recorded.

Total number correct

Praxis/ attention/
dexterity

Purdue Pegboard test26
2 min

The Purdue Pegboard Test consists of two rows of 25
vertically aligned holes and requires participants to
place as many pegs as possible in the holes.
Participants do this with their dominant hand, then
with their nondominant hand, and finally with both
hands, within 30 s per condition. The number of pegs
placed in the holes within the time frame is scored.

Dominant hand raw score

Orientation

CAMCOG-DS27

Participants are asked several questions regarding
orientation (name, place and time) with possibility of
prompts; potential range of scores between 0 and 12.

Total score

Memory

smaller numbers required), and avoiding inclusion of “non-converters

a broad range of baseline cognitive abilities. We identified a brief test

with mild cognitive impairment” as trial participants as often happens

battery, with elements that have been adapted for use in people with

in sporadic AD trials.4 A reliable outcome measure that can be used

DS, with considerable face validity for use to track AD-related decline.

to track treatment effects at early stages of decline would help enable

We then demonstrated observable effect sizes for longitudinal cogni-

successful clinical trials. However, such outcome measures should also

tive change across all study groups for the identified brief battery, in

be feasible, easy to administer internationally (independent of lan-

individuals at risk for but not yet presenting with diagnosable demen-

guage or cultural effects), and allow for a scores from participants with

tia due to AD.
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4.3

Further development

comparable to decline in other forms of AD, including sporadic AD and
autosomal-dominant AD. We have identified a composite that is sensi-

The H21 AD test battery will be included in our longitudinal studies of

tive to cognitive change during the early prodromal stage of AD in DS

cognitive decline associated with AD in DS. We will collect data on test-

prior to a diagnosis of dementia that can be used as an outcome mea-

retest reliability of this combination of subtests across cohorts, as well

sure in clinical trials of treatment to prevent or delay decline associated

as change in performance over time. This will allow for further analyses

with the disease in DS.

to consider refinement of scoring; for example, to consider the degree
each individual test contributes to an overall score to deliver addi-
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